دورية أكاديمية
أعرض في EDS

A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.

التفاصيل البيبلوغرافية
العنوان: A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.
المؤلفون: Mantiero M; Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Bini M; Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Polignano M; Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Porcu L; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK., Sanfilippo R; Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Fabbroni C; Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Parma G; Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy., Lapresa M; Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy., Calidona C; Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy.; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Piazzale Aristide Stefani 1, 37126 Verona, Italy., Silvestri C; Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Franza A; Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Raspagliesi F; Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy., Colombo N; Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy.; University of Milan-Bicocca, Piazza dell'Ateneo Nuovo 1, 20126 Milan, Italy., Ducceschi M; Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy.
المصدر: Cancers [Cancers (Basel)] 2023 Dec 30; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice.
Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey.
Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred.
Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.
References: J Clin Oncol. 2009 Jul 1;27(19):3154-60. (PMID: 19451429)
Jpn J Clin Oncol. 2015 May;45(5):449-55. (PMID: 25724217)
Gynecol Oncol. 2009 Dec;115(3):460-5. (PMID: 19811811)
Int J Gynaecol Obstet. 2009 Mar;104(3):177-8. (PMID: 19135669)
Signal Transduct Target Ther. 2019 May 17;4:16. (PMID: 31123606)
Jpn J Clin Oncol. 2018 Jun 1;48(6):503-513. (PMID: 29684209)
Lancet. 2012 May 19;379(9829):1879-86. (PMID: 22595799)
Expert Rev Anticancer Ther. 2012 Jun;12(6):711-23. (PMID: 22716487)
Cancers (Basel). 2022 Feb 24;14(5):. (PMID: 35267488)
Crit Rev Oncol Hematol. 2018 Feb;122:10-20. (PMID: 29458779)
Lancet Oncol. 2017 Oct;18(10):1397-1410. (PMID: 28882536)
Lancet Oncol. 2017 Nov;18(11):1493-1501. (PMID: 28988646)
Gynecol Oncol. 2018 Dec;151(3):562-572. (PMID: 30244960)
Gynecol Oncol. 2003 Jun;89(3):460-9. (PMID: 12798712)
Gynecol Oncol. 2016 Jul;142(1):89-94. (PMID: 27012429)
Gynecol Oncol. 1996 Aug;62(2):226-9. (PMID: 8751554)
Gynecol Oncol. 2005 Mar;96(3):749-52. (PMID: 15721421)
Acta Oncol. 2017 Dec;56(12):1769-1775. (PMID: 28723233)
J Gynecol Oncol. 2018 Jan;29(1):e3. (PMID: 29185261)
Curr Opin Oncol. 2013 Jul;25(4):373-8. (PMID: 23666473)
J BUON. 2019 Nov-Dec;24(6):2327-2332. (PMID: 31983102)
Cancers (Basel). 2022 Feb 12;14(4):. (PMID: 35205669)
Cancers (Basel). 2023 Mar 31;15(7):. (PMID: 37046760)
J Clin Oncol. 2016 Mar 10;34(8):786-93. (PMID: 26371143)
Eur J Cancer. 2020 Nov;139:149-168. (PMID: 32992154)
J Clin Oncol. 2015 Apr 1;33(10):1180-5. (PMID: 25713428)
Gynecol Oncol. 2010 Jan;116(1):131-9. (PMID: 19853898)
BMC Cancer. 2019 Aug 13;19(1):794. (PMID: 31409302)
فهرسة مساهمة: Keywords: effectiveness; pazopanib; safety; survival; uterine leyomiosarcoma
تواريخ الأحداث: Date Created: 20240111 Latest Revision: 20240114
رمز التحديث: 20240114
مُعرف محوري في PubMed: PMC10777896
DOI: 10.3390/cancers16010192
PMID: 38201619
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16010192